Novavax NVAX Total debt

Total debt at other companies

ModernaMRNA

$1.24B+60.8%

Vaxcyte, Inc.PCVX

$116.3M+33.5%

Merck & Co.MRK

$56.73B+54.0%

ALN

Alnylam PharmaceuticalsALNY

$256.43M-5.2%

Roivant SciencesROIV

$107.15M+7.5%

Gilead SciencesGILD

$26.25B+5.2%

FAQ

What is Novavax's total debt?

Novavax (NVAX) reported total debt of $297.32M in Q2 2026.

How has Novavax's total debt changed year-over-year?

Novavax's total debt increased by 413.3% year-over-year, from $57.92M to $297.32M.

What is the long-term trend for Novavax's total debt?

Over 5 years (2020 to 2025), Novavax's total debt has grown at a -1.7% compound annual growth rate (CAGR), from $305.79M to $280.56M.

What does total debt mean?

Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.